European Society of Cardiology: Edoxaban Vs. Edoxaban Plus an Antiplatelet Agent in Patients With Atrial Fibrillation and Stable Coronary Artery Disease
September 03, 2024
September 03, 2024
SOPHIA ANTIPOLIS, France, Sept. 3 (TNSres) -- The European Society of Cardiology issued the following news release:
* * *
Key take-aways
* In the EPIC-CAD trial, edoxaban monotherapy was associated with better net clinical benefit than edoxaban plus a single antiplatelet agent, when given as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation and stable coronary artery disease.
* The favourable clinical benefit ob . . .
* * *
Key take-aways
* In the EPIC-CAD trial, edoxaban monotherapy was associated with better net clinical benefit than edoxaban plus a single antiplatelet agent, when given as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation and stable coronary artery disease.
* The favourable clinical benefit ob . . .